clinical trial · NCT05392179
A Study in Subjects With Retinitis Pigmentosa
Retinitis PigmentosaADX-2191ADX-2191
brief summary
An open-label Phase II clinical trial, 8 (eight) subjects with retinitis pigmentosa due to rhodopsin mutations (including P23H) will be identified and treated with serial intravitreal injections of ADX-2191 in the worse seeing eye. Ocular structure and function will be evaluated.
started
Jul 14, 2022
primary completion
Jun 23, 2023
completion
Jun 23, 2023
last updated
Apr 23, 2026
official title
An Open-label, Phase II Study of ADX-2191 in Subjects With Retinitis Pigmentosa
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol